Shanghai Junshi Biosciences Co., Ltd. 1877.HK Stock
Shanghai Junshi Biosciences Co., Ltd. Price Chart
Shanghai Junshi Biosciences Co., Ltd. 1877.HK Financial and Trading Overview
Shanghai Junshi Biosciences Co., Ltd. stock price | 10.24 HKD |
Previous Close | 24.8 HKD |
Open | 24.75 HKD |
Bid | 25.15 HKD x 0 |
Ask | 25.2 HKD x 0 |
Day's Range | 24.5 - 26 HKD |
52 Week Range | 21.2 - 48.5 HKD |
Volume | 1.75M HKD |
Avg. Volume | 878.74K HKD |
Market Cap | 40.75B HKD |
Beta (5Y Monthly) | 0.426958 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.51 HKD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 56.51 HKD |
1877.HK Valuation Measures
Enterprise Value | 20.75B HKD |
Trailing P/E | N/A |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 37.757347 |
Price/Book (mrq) | 2.7701287 |
Enterprise Value/Revenue | 19.225 |
Enterprise Value/EBITDA | -7.422 |
Trading Information
Shanghai Junshi Biosciences Co., Ltd. Stock Price History
Beta (5Y Monthly) | 0.426958 |
52-Week Change | -44.70% |
S&P500 52-Week Change | 20.43% |
52 Week High | 48.5 HKD |
52 Week Low | 21.2 HKD |
50-Day Moving Average | 28.11 HKD |
200-Day Moving Average | 31.08 HKD |
1877.HK Share Statistics
Avg. Volume (3 month) | 878.74K HKD |
Avg. Daily Volume (10-Days) | 696.88K HKD |
Shares Outstanding | 219.3M |
Float | 607.45M |
Short Ratio | N/A |
% Held by Insiders | 22.84% |
% Held by Institutions | 31.06% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | -234.92% |
Operating Margin (ttm) | -280.60% |
Gross Margin | 58.56% |
EBITDA Margin | -259.021% |
Management Effectiveness
Return on Assets (ttm) | -16.39% |
Return on Equity (ttm) | -31.89% |
Income Statement
Revenue (ttm) | 1.08B HKD |
Revenue Per Share (ttm) | 1.15 HKD |
Quarterly Revenue Growth (yoy) | -59.50% |
Gross Profit (ttm) | 1.45B HKD |
EBITDA | -2795179520 HKD |
Net Income Avi to Common (ttm) | -2535086592 HKD |
Diluted EPS (ttm) | -2.92 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 5.42B HKD |
Total Cash Per Share (mrq) | 5.5 HKD |
Total Debt (mrq) | 1.39B HKD |
Total Debt/Equity (mrq) | 15.01 HKD |
Current Ratio (mrq) | 3.865 |
Book Value Per Share (mrq) | 9.079 |
Cash Flow Statement
Operating Cash Flow (ttm) | -3066884096 HKD |
Levered Free Cash Flow (ttm) | -2434676736 HKD |
Profile of Shanghai Junshi Biosciences Co., Ltd.
Country | Hong Kong |
State | N/A |
City | Shanghai |
Address | Building 7 |
ZIP | 200126 |
Phone | 86 21 6105 8800 |
Website | https://www.junshipharma.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 2961 |
Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in the therapeutic areas of oncology, metabolic, autoimmune, neurologic, and infectious diseases in the People's Republic of China. The company offers JS001, a recombinant humanized anti-PD-1 monoclonal antibody under the trade name of TUOYI for the indication of melanoma, mucosal melanoma, soft tissue sarcoma, nasopharyngeal carcinoma, urothelial carcinoma, non-small cell lung carcinoma, triple negative breast carcinoma, esophageal squamous cell carcinoma, and hepatocellular carcinoma. It is also developing UBP1211, a biosimilar of Humira for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriasis; JS002, a recombinant humanized anti-PCSK9 monoclonal antibody for treating hyperlipidemia; UBP1213, a recombinant humanized anti-BLyS monoclonal antibody for injection. In addition, the company is developing JS501, a biosimilar of Avastin; and JS003, a recombinant humanized anti-PD-L1 monoclonal antibody for injection; JS101, a pan-CDK inhibitor; TAB004/JS004, a recombinant humanized anti-BTLA monoclonal antibody for injection; and JS005, a recombinant humanized anti-IL-17A monoclonal antibody for injection. It has an agreement with Eli Lilly and Company to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, the disease caused by the SARS-CoV-2 novel coronavirus; and Coherus Biosciences, Inc. for the development and commercialization of toripalimab, Junshi Biosciences' anti-PD-1 antibody, as well as collaboration with Dr. Reddy's Laboratories Limited to develop and commercialize toripalimab, the anti-PD-1 monoclonal antibody. Shanghai Junshi Biosciences Co., Ltd. was founded in 2012 and is headquartered in Shanghai, People's Republic of China.
Q&A For Shanghai Junshi Biosciences Co., Ltd. Stock
What is a current 1877.HK stock price?
Shanghai Junshi Biosciences Co., Ltd. 1877.HK stock price today per share is 10.24 HKD.
How to purchase Shanghai Junshi Biosciences Co., Ltd. stock?
You can buy 1877.HK shares on the HKSE exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Shanghai Junshi Biosciences Co., Ltd.?
The stock symbol or ticker of Shanghai Junshi Biosciences Co., Ltd. is 1877.HK.
Which industry does the Shanghai Junshi Biosciences Co., Ltd. company belong to?
The Shanghai Junshi Biosciences Co., Ltd. industry is Biotechnology.
How many shares does Shanghai Junshi Biosciences Co., Ltd. have in circulation?
The max supply of Shanghai Junshi Biosciences Co., Ltd. shares is 2.27B.
What is Shanghai Junshi Biosciences Co., Ltd. Price to Earnings Ratio (PE Ratio)?
Shanghai Junshi Biosciences Co., Ltd. PE Ratio is now.
What was Shanghai Junshi Biosciences Co., Ltd. earnings per share over the trailing 12 months (TTM)?
Shanghai Junshi Biosciences Co., Ltd. EPS is -2.51 HKD over the trailing 12 months.
Which sector does the Shanghai Junshi Biosciences Co., Ltd. company belong to?
The Shanghai Junshi Biosciences Co., Ltd. sector is Healthcare.
Shanghai Junshi Biosciences Co., Ltd. 1877.HK included in indexes
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
---|
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
---|---|---|---|---|---|---|---|
{{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
Nasdaq EM Plus Korea Small Cap NQEMKRSCGBP | 1476.35 GBP 1888.16 USD |
<0.01
|
— — | 1476.35 GBP 1888.16 USD | 1476.35 GBP 1888.16 USD | — - | — — |
- {{ link.label }} {{link}}
Stocks Related By Sector
- Shandong Weigao Group Medical Polymer Company Limited 1066.HK Stock
- China Traditional Chinese Medicine Holdings Co. Limited 0570.HK Stock
- Hygeia Healthcare Holdings Co., Limited 6078.HK Stock
- The United Laboratories International Holdings Limited 3933.HK Stock
- China Medical System Holdings Limited 0867.HK Stock